Tuesday, August 4, 2015

India's Sitagliptin Wars Update: Glenmark On Market Only Until Q4 2015, Now

So -- no interim relief for Glenmark, to dispose of its raw materials inventory -- via continued manufacturing, from APIs. However, by most calculations, including mine, Glenmark has enough finished goods inventory to supply the Indian market demand for generic sitagliptin through November of 2015. And we should have a final outcome a month or so before then, in India in any event. [Backgrounder here.]

Here is the local coverage, just filed this afternoon, New York time:

. . . .A bench comprising justices Ranjan Gogoi and N. V. Ramana said it didn’t consider it appropriate to create additional rights in favour of Glenmark at this stage, when the Delhi High Court hearing on the dispute between Glenmark and US-based Merck, Sharpe and Dohme (MSD) is about to conclude.

"The registrar of the Delhi High Court is also directed to inform this court about the pending suit relating to the patent infringement after the judgement is delivered by the High Court," the bench said. . . .

Onward, then on a hazy August Tuesday. . .


No comments: